Patient Characteristics

Treatment Arms Were Balanced in the Phase 3 NOVA Study of ZEJULA1

Reference: 1. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164.

Study design

STUDY DESIGN

See the clinical rigor behind the pivotal trial design for ZEJULA

View Trial Info

Efficacy summary

EFFICACY DATA

See PFS in HRDpos and HRDneg patient subgroups

View Efficacy

Safety data

SAFETY DATA

Learn about the safety and tolerability of ZEJULA

See Safety

Pivotal trial

PIVOTAL TRIAL

See the pivotal phase 3 trial publication

Access Publication